Document is current
Any future updates will be listed below
-
Authors
Lanteri-Minet, M.
Casarotto, C.
Bretin, O.
Collin, C.
Gugenheim, M.
Raclot, V.
Cases, A.
Squara, P. A.
Aissani, W.
Saighi, A.
Lefebvre, H.
-
Funding
Funding for this research was provided by:
Pfizer France
- License Information
-
More Information
Article History
Received: 11 March 2025
Accepted: 4 June 2025
First Online: 2 July 2025
Declarations
:
: Patients are individually informed before data collection by the practitioner that information from their medical files may be used for scientific purposes in an anonymous manner and in compliance with medical secrecy. Patients are informed in advance to allow them, if necessary, to object to the processing of their data even before they are collected by IQVIA. In addition, measures will be taken to make information publicly available regarding the implementation of these treatments. These measures will be visible on the IQVIA France website in a specific personal data section (link to the IQVIA website) and include: a general information notice (link to the General Information Notice) applicable to EMR data and an information notice specific to the study.
: Not applicable.
: EC, OB and CC declare to have no competing interest.AC, PAS, WA, AS and HL are employees of Pfizer France.ML-M reports personal fee for advisory boards, speaker panels or investigation studies from Allergan/Abbvie, Amgen, Astellas, ATI, BMS, Boehringer, Boston Scientific, CoLucid, Convergence, Eli Lilly, GlaxoSmithKline, Grunenthal, Eli Lilly, IPSEN, Lundbeck, Medtronic, MSD, Novartis, Orion Pharma, PerFood, Pfizer, ReckittBenckiser, Saint-Jude, Salvia BioElectronics, Sanofi-Aventis, Teva, UCB, UPSA and Zambon.MG has received speaker/advisory board honoraria from Sanofi-Genzyme, Alexion, Pfizer and Biogen. VR has received speaker/advisory board honoraria from Lundbeck and Pfizer.
